MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study
- 1 February 2017
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 18 (2) , 192-201
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Interleukin-1α neutralisation in patients with cancerThe Lancet Oncology, 2014
- Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010The Lancet, 2012
- Interleukin 1α Sustains the Expression of Inflammatory Factors in Human Pancreatic Cancer Microenvironment by Targeting Cancer-Associated FibroblastsNeoplasia, 2011
- The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactionsCancer and Metastasis Reviews, 2006
- Interleukin‐1 (IL‐1α and IL‐1β) and its receptors (IL‐1RI, IL‐1RII, and IL‐1Ra) in prostate carcinomaCancer, 2004
- IL-1 is required for tumor invasiveness and angiogenesisProceedings of the National Academy of Sciences, 2003
- Interleukin‐1α (IL‐1α) promotes angiogenesis in vivo via VEGFR‐2 pathway by inducing inflammatory cell VEGF synthesis and secretionThe FASEB Journal, 2002
- Significant correlation between expression of interleukin-1? and liver metastasis in gastric carcinomaCancer, 2001
- Interleukin-1 Family Expression in Human Breast Cancer: Interleukin-1 Receptor AntagonistCancer Investigation, 2000
- Incidence and patterns of recurrence following curative resection for colorectal carcinomaDiseases of the Colon & Rectum, 1997